Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Employees

376

Sector

Biotechnology & Medical Research

Calendar

05/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
16/09/24	233.39 $	-3.48%	195,897
13/09/24	241.80 $	+3.00%	195,775
12/09/24	234.76 $	+0.76%	112,238
11/09/24	233.00 $	-1.14%	195,649
10/09/24	235.69 $	-1.26%	201,232

Delayed Quote Nasdaq, September 16, 2024 at 09:00 pm

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

233.39USD

Average target price

360.57USD

Spread / Average Target

+54.49%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 16/09/2024 BST			5-day change	1st Jan Change
233.39 ^USD	-3.48%		-2.22%	+0.87%

09-12	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,551,490, According to a Recent SEC Filing	MT
09-05	Transcript : Madrigal Pharmaceuticals, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:45 AM

Capitalization	5.07B 383B	P/E ratio 2024 *	-8.01x	P/E ratio 2025 *	-13.2x
Enterprise value	4.05B 306B	EV / Sales 2024 *	43x	EV / Sales 2025 *	10x
Free-Float	83.84%	Yield 2024 *	-	Yield 2025 *	-

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,551,490, According to a Recent SEC Filing	09-12	MT
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:45 AM	09-05
B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $194 From $200, Maintains Neutral Rating	08-08	MT
Madrigal Pharmaceuticals Reports Q2 Revenue as Loss Widens; Shares Gain Pre-Bell	08-07	MT
Transcript : Madrigal Pharmaceuticals, Inc., Q2 2024 Earnings Call, Aug 07, 2024	08-07
Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Posts Q2 Loss $-7.10, vs. Street Est of $-7.61	08-07	MT
Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Posts Q2 Loss $-7.10 Per Share, vs. Street Est of Loss $-7.66 Per Share	08-07	MT
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-07	CI
Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel	08-02	CI
JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating	07-16	MT
Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating	06-28	MT
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	06-11
Madrigal Pharmaceuticals Reports Positive Results in New Analysis of Phase 3 Trial of NASH Drug Rezdiffra	06-06	MT

B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $194 From $200, Maintains Neutral Rating	08-08	MT
JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating	07-16	MT
Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating	06-28	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing	05-17	MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating	05-10	MT

Madrigal Pharmaceuticals, Inc. Share Price

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Valuation: Madrigal Pharmaceuticals, Inc.

Chart: Madrigal Pharmaceuticals, Inc.

Latest news: Madrigal Pharmaceuticals, Inc.

Last Transcript: Madrigal Pharmaceuticals, Inc.

Analysts' recommendations: Madrigal Pharmaceuticals, Inc.

Press Releases: Madrigal Pharmaceuticals, Inc.

News in other languages: Madrigal Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Madrigal Pharmaceuticals, Inc.

ETFs: Madrigal Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly earnings, Rate of surprise

Madrigal Pharmaceuticals : Corporate Code of Conduct	08-29	PU
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference	08-27	AQ
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference	08-26	AQ
Madrigal Pharmaceuticals : Second-Quarter 2024 Financial Results Presentation	08-07	PU
Madrigal: Q2 Earnings Snapshot	08-07	AQ

EE.UU. - Valores a seguir en Wall Street (actualizado)	03-19
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -	03-19
Madrigal Pharmaceuticals : lève 600 millions de dollars pour le lancement de son Rezdiffra	03-19
Wall Street ouvre en baisse, les regards tournés vers la Fed	03-15
EE.UU. - Valores a seguir en Wall Street (actualizado)	03-15

1 day	-3.48%
1 week	-2.22%
Current month	-5.56%
1 month	-6.95%
3 months	-15.92%
6 months	-13.68%
Current year	+0.87%

Director	Title	Age	Since
William Sibold CEO	Chief Executive Officer	57	07/09/23
Edward Chiang FOU	Founder	-	31/08/11
Rebecca Taub FOU	Founder	71	30/06/16

Manager	Title	Age	Since
Paul Friedman BRD	Director/Board Member	81	21/07/16
Rebecca Taub FOU	Founder	71	30/06/16
Fred Craves FOU	Founder	78	31/08/11

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.35%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.08%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
MADRIGAL PHARMACEUTICALS, INC.	-3.48%	-2.22%	+32.69%	+191.19%	5.07B
VERTEX PHARMACEUTICALS INCORPORATED	+0.84%	+3.89%	+40.28%	+161.59%	126B
REGENERON PHARMACEUTICALS, INC.	-0.02%	+0.73%	+40.04%	+76.53%	124B
ARGENX SE	+0.47%	-0.08%	-0.08%	+74.15%	32.29B
BIONTECH SE	+0.06%	+22.82%	+9.21%	-66.87%	29.36B
SUMMIT THERAPEUTICS INC.	-7.67%	+54.02%	+1,476.47%	+354.24%	21.66B
BEIGENE, LTD.	-1.03%	+1.62%	-1.93%	-49.01%	20.89B
GENMAB A/S	-0.06%	-4.23%	-31.77%	-33.28%	16.82B
WUXI APPTEC CO., LTD.	+0.15%	+1.04%	-50.10%	-72.38%	16.04B
VAXCYTE, INC.	-1.52%	-0.90%	+120.88%	+333.22%	14.13B
Average	-0.45%	+7.53%	+163.57%	+96.94%	40.7B
Weighted average by Cap.	+0.15%	+6.00%	+105.20%	+100.67%

	2024 *	2025 *
Net sales	101M 7.63B	473M 35.78B
Net income	-615M -46.53B	-407M -30.78B
Net Debt	-733M -55.49B	-324M -24.54B